Merck KGaA makes $600M bet to boost manufacturing for viral vectors

Mer­ck KGaA an­nounced Wednes­day that it is ac­quir­ing Mirus Bio, a start­up that de­vel­ops trans­fec­tion reagents for vi­ral cell and gene ther­a­pies, for $600 mil­lion.

“Com­bin­ing Mirus Bio’s lead­ing tech­nol­o­gy with our bio­pro­cess­ing ex­per­tise and port­fo­lio al­lows us to pro­vide so­lu­tions for al­most every step of vi­ral vec­tor de­vel­op­ment and man­u­fac­tur­ing,” Mer­ck KGaA board mem­ber Matthias Heinzel said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.